DiaSorin SpA
John Hoffarth's work experience includes various roles in finance and accounting.
From 2018 to the present, they have served as the Vice President of Accounting, Tax & Treasury North America at DiaSorin, where they lead a team of professionals and oversees financial reporting, tax, and treasury operations.
Prior to this, from 2012 to 2020, John had positions in the Army National Guard, including Battalion Staff Officer, Company Commander, and Platoon Leader / Brigade Staff Officer.
From 2016 to 2018, they worked at Vascular Solutions (now part of Teleflex) as an Assistant Controller / Controller.
Before that, from 2012 to 2016, John was a Senior Associate at PwC, where they focused on risk assurance and private company services.
Overall, John has gained extensive experience in finance, accounting, and leadership roles throughout their career.
John Hoffarth attended Jefferson Senior High School, although the start and end years are not mentioned. John then went on to earn a Bachelor of Accountancy degree from the University of North Dakota, graduating in 2011.
This person is not in any offices
DiaSorin SpA
4 followers
DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company's business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.